A cluster of capital-market moves underscored continued investor appetite for biotech, particularly in larger, near-term commercialization paths. Latigo Biotherapeutics priced an IPO at roughly $346 million for a non-opioid pain program targeting Nav1.8, positioning the company to compete in ion-channel therapeutics. Blossomhill Therapeutics followed with a $150 million IPO to fund a macrocyclic cancer drug pipeline aimed at targets including EGFR-mutant non-small-cell lung cancer. Both offerings fit the current pattern of upsized IPOs, suggesting market preference for differentiated mechanisms and clear regulatory or clinical advancement timelines.